Statin therapy and atherosclerosis stabilization in carotid arteries

Cover Page

Cite item

Full Text

Abstract

Atherosclerosis and it’s clinical implications (myocardial infarction, stroke, intermittent lameness) is a serious medico-social problem in Russia. Statins (or HMG-CoA reductase inhibitors) are the first-choice agents to prevent cardiovascular disease events. The paper presents the results of early regression studies and modern regression studies using MRI imaging concerning the regression or stabilization atherosclerosis and rationale and baseline characteristics of russian regression study “FREGAT”.

About the authors

Z. G Luginova

Federal state budget foundation Russian cardiology scientific and production complex of the Ministry of Health of the Russian Federation

Email: luginovazoya@gmail.com
аспирантка лаб. клинической липидологии отд. проблем атеросклероза ИКК им.А.Л.МясниковаФГБУРКНПК 121552, Russian Federation, Moscow, ul. 3-ya Cherepkovskaya, d. 15a

M. V Koshurnikova

Federal state budget foundation Russian cardiology scientific and production complex of the Ministry of Health of the Russian Federation

канд. мед. наук, лаборант-исследователь лаб. ультразвуковых методов исследо- вания сосудов отд. новых методов диагностики ИКК им. А.Л.Мясникова ФГБУ РКНПК 121552, Russian Federation, Moscow, ul. 3-ya Cherepkovskaya, d. 15a

E. Yu Solovieva

Federal state budget foundation Russian cardiology scientific and production complex of the Ministry of Health of the Russian Federation

канд. мед. наук, науч. сотр. лаб. клинической липидологии отд. проблем атеросклероза ИКК им. А.Л.Мясникова ФГБУ РКНПК 121552, Russian Federation, Moscow, ul. 3-ya Cherepkovskaya, d. 15a

T. V Balakhonova

Federal state budget foundation Russian cardiology scientific and production complex of the Ministry of Health of the Russian Federation

д-р мед. наук, проф., рук. лаб. ультразвуковых методов исследования сосудов отд. новых методов диагностики ИКК им. А.Л.Мясникова ФГБУ РКНПК 121552, Russian Federation, Moscow, ul. 3-ya Cherepkovskaya, d. 15a

A. V Susekov

Federal state budget foundation Russian cardiology scientific and production complex of the Ministry of Health of the Russian Federation

д-р мед. наук, вед. науч. сотр., рук. лаб. клинической липидологии отд. проблем атеросклероза ИКК им. А.Л.Мясникова ФГБУ РКНПК 121552, Russian Federation, Moscow, ul. 3-ya Cherepkovskaya, d. 15a

References

  1. Шальнова С.А., Деев А.Д. Тенденции смертности в России в начале XXI в. (по данным официальной статистики). Кардиоваск. терапия и профилактика. 2011; 10 (6): 5-10.
  2. Демографический ежегодник России. 2010.
  3. ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis 2011; p. 217S.S1-S44
  4. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза: Российские рекомендации (V пересмотр). Атеросклероз и дислипидемии. 2012; 4 (9)
  5. Оганов Р.Г., Кухарчук В.В., Арутюнов Г.П. и др. Сохраняющиеся нарушения липидного спектра у пациентов с дислипидемиями, получающих статины в реальной клинической практике в РФ (российская часть исследования DYSIS). Кардиоваск. терапия и профилактика. 2012; 4: 1-10.
  6. Amarenco P, Labreuche J, Lavalle´e P, Touboul P.J. Statins in stroke prevention and carotid atherosclerosis: systematic review and up - to - date meta - analysis. Stroke 2004; 35: 2902-9.
  7. Рекомендации Европейского общества кардиологов и Европейского общества атеросклероза по лечению дислипидемий. Рацион. фармакотерапия в кардиологии. 2012 (Прил. 1).
  8. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. 5-й пересмотр. М., 2012.
  9. Национальные рекомендации по ведению пациентов с сосудистой артериальной гипертензией (Российский согласительный документ). Российское общество ангиологов и сосудистых хирургов, Ассоциация сердечно - сосудистых хирургов. М., 2012.
  10. Koenig W. Atherosclerosis involves more than just lipids: focus on inflammation. Eur Heart J 1999; 1 (Suppl. 1): 19-26.
  11. Ross R. Atherosclerosis an inflammatory disease. N Engl J Med 1999; 340: 115-26.
  12. Nordestgaard B.G, Grønholdt M.L, Sillesen H et al. Echolucent ruptureprone plaques. Curr Opin Lipidol 2003; 14 (5): 505-12.
  13. Puato M, Zambon A, Faggin E et al. Statin treatment and carotid plaque composition. Review of clinical studies. Curr Vasc Pharmacol 2012.
  14. Hodis H.N, Mack W.J, La Bree L et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomised, controlled clinical trial. Ann Intern Med 1996; 24: 548-56.
  15. Kroon A.A, Asten van W.N.J.C, Stalenhoef A.F.H. Effects of apheresis of low - density lipoprotein on peripheral vascular disease in hypercholesterolaemic patients with coronary artery disease. Ann Intern Med 1996; 125: 945-54.
  16. Amtzenius A.C, Kromhout D, Barth J.D et al. Diet, lipoproteins and the progression of coronary atherosclerosis. The Leiden Intervention. Trial N Engl J Med 1985; 312 (13): 805-11.
  17. Brown G, Albers J.J, Fisher L.D et al. Regression of coronary artery disease as a result of intensive lipid - lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289-98.
  18. Stone N.J, Robinson J.G, Lichtenstein A.H et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129 (25 Suppl. 2): S1-45.
  19. Furberg C.D, Adams Jr H.P, Applegate W.B et al. For the Asymptomatic Carotid Artery Progression Study (ACAPS) research group. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994; 90: 1679e87.
  20. Mercuri M, Bond M.G, Sirtori C.R et al. Pravastatin reduces carotid intima - media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study (CAIUS). Am J Med 1996; 101: 627e34.
  21. De Groot E, Zwinderman A.H, van der Steen A.F et al. Variance components analysis of carotid and femoral intima - media thickness measurements. REGRESS Study Group. Interuniversity Cardiology Institute of The Netherlands, Utrecht, The Netherlands. Regression growth evaluation statin study. Ultrasound Med Biol 1998; 24: 825e32.
  22. Mac Mahon S, Sharpe N, Gamble G et al. Effects of lowering average of below average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. Circulation 1998; 97: 1784e90.
  23. Taylor A.J, Kent S.M, Flaherty P.J et al. ARBITER: arterial biology for the investigation of the treatment effects of reducing cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima - medial thickness. Circulation 2002; 106: 2055e60.
  24. De Sauvage N, De Groot E, Zwinderman A.H et al. Regression of carotid and femoral artery intima - media thickness in familial hypercholesterolemia: treatment with simvastatin. Arch Intern Med 2003; 163: 1837e41.
  25. Smilde T.J, van W.S, Wollersheim H et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double - blind trial. Lancet 2001; 357: 577e81.
  26. Crouse J.R, Raichlen J.S, Riley W.A et al. Effect of rosuvastatin on progression of carotid intima - media thickness in low - risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007; 297: 1344e53.
  27. Underhill H.R, Yuan C, Zhao X.Q et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high - resolution magnetic resonance imaging trial. Am Heart J 2008; 155 (584): e1-8.
  28. Miyauchi K, Takaya N, Hirose T et al. Rationale and design of the carotid plaque in human for all evaluations with aggressive rosuvastatin therapy (CHALLENGER trial): evaluation by magnetic resonance imaging. Circ J 2009; 73 (1): 111-5.
  29. Saam T, Kerwin W.S, Chu B et al. Sample size calculation for clinical trials using magnetic resonance imaging for the quantitative assessment of carotid atherosclerosis. J Cardiovasc Magn Reson 2005; 7: 799-808.
  30. Takaya N, Yuan C, Chu B et al. Presence of intraplaque hemorrhage stimulates progression of carotid atherosclerotic plaques: a high resolution magnetic resonance imaging study. Circulation 2005; 111: 2768-75.
  31. Saam T, Yuan C, Chu B et al. Predictors of carotid atherosclerotic plaque progression as measured by noninvasive magnetic resonance imaging. Atherosclerosis 2007; 194: e34-42.
  32. Corti R, Fayad Z.A, Fuster V et al. Effects of lipid - lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high - resolution, noninvasive magnetic resonance imaging. Circulation 2001; 104: 249e52.
  33. Corti R, Fuster V, Fayad Z.A et al. Effects of aggressive versus conventional lipid - lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double - blind trial with high - resolution magnetic resonance imaging. J Am Coll Cardiol 2005; 46: 106e12.
  34. Adam M. Noyes, Paul D. Thompson. A systematic review of the time course of atherosclerotic plaque Regression. Atherosclerosis 2014; 234 (1): 75-84.
  35. Salonen R, Nyyssonen K, Porkkala E et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population - based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995; 92: 1758e64.
  36. Takahashi T, Ishii N, Itai K et al. HMG-CoA reductase inhibitors suppress the development and progression of carotid artery intimal medial thickening in hypercholesterolemic type 2 diabetic patients. J Atheroscler Thromb 2005; 12: 149e53.
  37. Yu C.M, Zhang Q, Lam L et al. Comparison of intensive and low - dose atorvastatin therapy in the reduction of carotid intimal - medial thickness in patients with coronary heart disease. Heart 2007; 93: 933e9.
  38. Crouse J.R, Byington R.P, Bond M.G. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol 1995; 75: 455e9.
  39. Beishuizen E.D, van de Ree M.A, Jukema J.W et al. Two - year statin therapy does not alter the progression of intima - media thickness in patients with type 2 diabetes without manifest cardiovascular disease. Diabetes Care 2004; 12: 2887e92.
  40. Bots M.L, Visseren F.L, Evans G.W et al. Torcetrapib and carotid intima - media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double - blind trial. Lancet 2007; 370: 153e60.
  41. Kastelein J.J, van Leuven S.I, Burgess L et al. Effect of torcetrapib on carotida the rosclerosis in familial hypercholesterolemia. N Engl J Med 2007; 356: 1620e30.
  42. Ainsworth C.D, Blake C.C, Tamayo A et al. 3D Ultrasound Measurement of Change in Carotid Plaque Volume: A Tool for Rapid Evaluation of New Therapies. Stroke 2005; 36: 1904-9.
  43. Kiyofumi Y, Shinichi Y, Masanori K et al. Effects of Atorvastatin on Carotid Atherosclerotic Plaques: A Randomized Trial for Quantitative Tissue Characterization of Carotid Atherosclerotic Plaques with Integrated Backscatter Ultrasound. Cerebrovasc Dis 2009; 28: 417-24.
  44. Nakamura T, Obata J.E, Kitta Y, Takano H et al. Rapid stabilization of vulnerable carotid plaque within 1 month of pitavastatin treatment in patients with acute coronary syndrome. J Cardiovasc Pharmacol 2008; 51 (4): 365-71.
  45. Schminke U, Motsch L, Griewing B et al. Three - dimensional power - mode ultrasound for quantification of the progression of carotid artery atherosclerosis. J Neurol 2000; 247: 106-11.
  46. Steinke W, Hennerici M. Three - dimensional ultrasound imaging of carotid artery plaques. J Card Tech 1989; 8: 15-22.
  47. Schminke U.L, Motsch L, Hilker L, Kessler C. Three - dimensional ultrasound observation of carotid artery plaque ulceration. Stroke 2000; 31: 1651-5.
  48. Кошурникова М.В., Балахонова Т.В., Карпов Ю.А. Возможности ультразвуковой трехмерной визуализации при изучении размеров и структуры атеросклеротической бляшки. Атеросклероз и дислипидемии. 2013; 4: 31-9.
  49. Зубарева М.Ю., Рожкова Т.А., Амелюшкина В.А. и др. Эффективность, безопасность и переносимость терапии розувастатином 40 мг/сут у больных очень высокого сердечно - сосудистого риска с первичной гиперхолестеринемией (результаты 24-недельного исследования «40×40»). Фарматека. 2013; 7: 63-8.
  50. Kekes E, Csaszar A. Testing the anti - lipid properties of rosuvastatin - a non - interventional, observational clinical study (TIGER). Cardiol Hungarica 2012; 42 (2): 61-7.
  51. Гиляревский С.Р., Орлов В.А., Кузьмина И.М. и др. Гиполипидемические эффекты применения интенсивных режимов приема статинов при лечении больных с острым коронарным синдромом: подходы к выбору препарата и его дозы. Кардиология и сердечно - сосудистая хирургия. 2012; 4: 36-41.
  52. Драпкина О.М., Палаткина Л.О., Зятенкова Е.В. Плейотропные эффекты статинов. Влияние на жесткость сосудов. Врач. 2012; 9: 5-8.
  53. Задионченко В.С., Шехян Г.Г., Шахрай Н.Б. и др. Влияние розувастатина на липидный обмен, микроциркуляцию и показатели центральной гемодинамики у больных с острым коронарным синдромом. Consilium Medicum. 2011; 13 (5): 3-10.
  54. Каминный А.И., Шувалова Ю.А., Шишова Т.А., Каминная В.И., Тутунов В.С., Соболева Д.И., Кухарчук В.В. Эффективность и безопасность терапии розувастатином. Результаты 8- недельного исследования «От 5 до 40». Фарматека 2014; 13: 40.

Copyright (c) 2015 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies